JW (Cayman) Therapeutics Co Ltd

HKSE:02126 (China)   Ordinary Shares
HK$ 1.30 (+0.78%) Dec 24
At Loss
P/B:
0.34
Market Cap:
HK$ 539.59M ($ 69.47M)
Enterprise V:
HK$ 15.29M ($ 2.48M)
Volume:
499.50K
Avg Vol (2M):
555.45K
Trade In:
Volume:
499.50K
At Loss
Avg Vol (2M):
555.45K

Business Description

Description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Name Current Vs Industry Vs History
Cash-To-Debt 2.28
Equity-to-Asset 0.75
Debt-to-Equity 0.26
Debt-to-EBITDA -0.62
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.23
Distress
Grey
Safe
Beneish M-Score -3.78
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 43.54
9-Day RSI 44.62
14-Day RSI 44.87
6-1 Month Momentum % -30.89
12-1 Month Momentum % -41.07

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.92
Quick Ratio 2.76
Cash Ratio 2.69
Days Inventory 179.63
Days Sales Outstanding 11.52
Days Payable 37.93

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.1
Shareholder Yield % -1.85

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 50.4
Operating Margin % -290.64
Net Margin % -363.75
FCF Margin % -213.37
ROE % -35.44
ROA % -27.75
ROIC % -36.33
ROC (Joel Greenblatt) % -180.71
ROCE % -31.53

Financials

HKSE:02126's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

JW (Cayman) Therapeutics Co Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil HK$) 187.652
EPS (TTM) (HK$) -1.652
Beta 1.87
Volatility % 83.19
14-Day RSI 44.87
14-Day ATR (HK$) 0.076025
20-Day SMA (HK$) 1.3325
12-1 Month Momentum % -41.07
52-Week Range (HK$) 1.19 - 2.68
Shares Outstanding (Mil) 415.07

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

JW (Cayman) Therapeutics Co Ltd Filings

Filing Date Document Date Form
No Filing Data

JW (Cayman) Therapeutics Co Ltd Stock Events

Financials Calendars
Event Date Price(HK$)
No Event Data

JW (Cayman) Therapeutics Co Ltd Frequently Asked Questions

What is JW (Cayman) Therapeutics Co Ltd(HKSE:02126)'s stock price today?
The current price of HKSE:02126 is HK$1.30. The 52 week high of HKSE:02126 is HK$2.68 and 52 week low is HK$1.19.
When is next earnings date of JW (Cayman) Therapeutics Co Ltd(HKSE:02126)?
The next earnings date of JW (Cayman) Therapeutics Co Ltd(HKSE:02126) is .
Does JW (Cayman) Therapeutics Co Ltd(HKSE:02126) pay dividends? If so, how much?
JW (Cayman) Therapeutics Co Ltd(HKSE:02126) does not pay dividend.

Press Release

Subject Date
No Press Release